What You Should Know:
– OMNY Health, the leading healthcare ecosystem for compliant real-world data insights at scale, and Scipher Medicine, which has the world’s largest immunology clinico-transcriptomics data set and is focused on advancing precision medicine with proprietary AI network biology solutions, today announced a partnership to advance precision medicine efforts for immunology.
– This collaboration marks a significant leap forward in the fight against autoimmune diseases, integrating transcriptomic data from Scipher Medicine with OMNY Health’s vast EHR network that reaches more than 80 million patients. OMNY Health’s network includes data from nearly 250,000 patients with rheumatoid arthritis, covering key metrics such as functional status, lab values (ESR, CRP), joint counts, CDAI, and DAS28, which enables comprehensive tracking of patient outcomes and disease progression.
OMNY Health and Scipher Medicine Collaborate to Advance Precision Medicine through Data-Driven Insights
OMNY Health™ operates a robust national data ecosystem that connects healthcare networks, academic medical centers, and integrated delivery networks across all 50 states. With access to over 75 million patient lives, more than 2 billion clinical notes, and over 300,000 providers spanning 200+ specialties, OMNY Health’s platform empowers innovation in healthcare by serving as a centralized resource for data sharing and collaborative research.
The company’s comprehensive data layer enables life sciences and healthcare providers to share data at scale, facilitating advancements in clinical outcomes and patient care. Notably, the platform has recently launched a GLP-1 database with over 600,000 datasets, focusing on pediatrics and social determinants of health, further strengthening its research capabilities in diverse healthcare areas.
In partnership with Scipher Medicine, OMNY Health integrates detailed clinical data with the genomic insights provided by PrismRA, a personalized blood test for rheumatoid arthritis. PrismRA has already tested over 40,000 rheumatoid arthritis patients and is the only classifier approved by the Centers for Medicare & Medicaid Services (CMS) in the U.S. This collaboration enables researchers to access comprehensive clinico-transcriptomic datasets, enhancing the identification of new patient groups and the development of targeted therapies.
OMNY Health’s data-driven approach is aligned with the growing role of biomarkers in medicine. With biomarker-dependent drugs comprising 42% of FDA approvals, the partnership between OMNY Health and Scipher Medicine is poised to support drug developers in expanding precision medicine therapies. The collaboration provides a holistic view of patient journeys, combining treatment response data with genomic and clinical insights to improve patient outcomes.
Dr. Mitesh Rao, Founder and CEO of OMNY Health, highlighted the importance of leveraging data for precision medicine: “Nearly 50 million Americans suffer from autoimmune diseases, and their experiences hold valuable insights. Extracting these insights is key to driving advancements in precision medicine.”
Through dynamic partnerships and a commitment to innovation, OMNY Health continues to expand its ecosystem, supporting healthcare providers and life sciences organizations in their mission to deliver more effective, patient-centric therapies.
